Document Detail


Regeneration of chronic tympanic membrane perforation using an EGF-releasing chitosan patch.
MedLine Citation:
PMID:  23627815     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Most chronic tympanic membrane (TM) perforations require surgical interventions such as tympanoplasty because, unlike with acute perforations, it is very difficult for the perforations to heal spontaneously. The purpose of this study was to develop novel therapeutic techniques and scaffolds that release growth factors to treat chronic TM perforations. We evaluated the cell proliferation effects of the epidermal growth factor (EGF) and fibroblast growth factor (FGF) on in vitro cultures of TM cells using an MTT assay. They both showed similar efficacy, so we used EGF because of its lower cost. We then constructed an EGF-releasing chitosan patch scaffold (EGF-CPS) based on previous studies. We analyzed its toxicity and strength, and we studied it using scanning electron microscopy. EGF was released from the EGF-CPS for 8 weeks in an in vitro system. In animal studies, the EGF group, which was treated with EGF-CPS, showed healing in 56.5% of the animals (13/23), while the control group, which did not receive any treatment, revealed 20.8% healing (4/24) (p=0.04). Transmission electron microscopic studies of regenerated eardrums in the EGF group showed much greater preservation of histological features, and TMs of the EGF group were thinner than spontaneously healed TMs. In conclusion, this novel EGF-CPS can be used as a nonsurgical intervention technique for treatment of chronic TM perforations.
Authors:
Hoon Seonwoo; Seung Won Kim; Jangho Kim; Tian Chunjie; Ki Taek Lim; Yeon Ju Kim; Shambhavi Pandey; Pill-Hoon Choung; Yun-Hoon Choung; Jong Hoon Chung
Related Documents :
23240565 - Cellular acidosis inhibits assembly, disassembly, and motility of stress granules.
2529725 - In vitro ige-secretion in atopic eczema: influence of allergens and mitogens and role o...
1404155 - Mechanisms of pathogenesis in scleroderma. i. overproduction of interleukin 6 by fibrob...
7349025 - Presence of helper or suppressor factors to ige synthesis in the serum of atopic and no...
1733715 - Luteinizing hormone differentially regulates the secretion of testicular oxytocin and t...
17828495 - Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expressio...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Tissue engineering. Part A     Volume:  19     ISSN:  1937-335X     ISO Abbreviation:  Tissue Eng Part A     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-07-29     Completed Date:  2014-03-13     Revised Date:  2014-09-02    
Medline Journal Info:
Nlm Unique ID:  101466659     Medline TA:  Tissue Eng Part A     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2097-107     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Survival / drug effects
Chitosan / chemistry*
Epidermal Growth Factor / chemistry*,  therapeutic use*
Female
Rats
Rats, Sprague-Dawley
Tympanic Membrane Perforation / drug therapy*,  therapy*
Wound Healing / drug effects
Chemical
Reg. No./Substance:
62229-50-9/Epidermal Growth Factor; 9012-76-4/Chitosan
Comments/Corrections
Comment In:
Tissue Eng Part A. 2013 Oct;19(19-20):2109-10   [PMID:  23859315 ]
Tissue Eng Part A. 2013 Oct;19(19-20):2110-1   [PMID:  23865585 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adenoma, advanced adenoma and colorectal cancer prevalence in asymptomatic 40 to 49-year-olds with a...
Next Document:  Validation of self-reported cannabis dose and potency: an ecological study.